ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
‘Frame running’ may help boost physical activity in MS
‘Frame running’ uses a three-wheeled frame with a saddle and body supports but no pedals to allow individuals with disabilities and balance...
Conference Coverage
MS, DMTs, and pregnancy: Beware of over-caution regarding treatment
Don’t be too quick to stop therapy or too slow to restart it, researcher tells ECTRIMS audience.
Conference Coverage
Wearable devices show promise in monitoring multiple sclerosis
Further analysis may allow the prediction of “relevant changes throughout the course of multiple sclerosis.”
Conference Coverage
NMO: Study says double diagnoses with MS are common
Nearly half of patients with coding for NMO were also listed as having MS – a very similar condition.
Conference Coverage
EBV and MS: Just how deep is the link?
Two MS researchers disagree over how tightly they’re connected, and one says “second hit” may be factor.
Conference Coverage
Stem cell transplants in early MS: Who benefits most?
Neurologists outline findings as the MS field works toward consensus on HSCT as rescue therapy.
Conference Coverage
MS-tailored weight loss program achieves meaningful results
Weight loss “was associated with improved mobility, reduced fatigability, and improved physical quality of life.”
Conference Coverage
‘We’re halfway home’: UCSF’s Dr. Stephen Hauser sketches MS future
Identification of a reliable MS biomarker as well as early detection and intervention will be key going forward.
Conference Coverage
Next up in MS trials: More insight into progressive disease
Results from several treatment trials in progressive MS are expected over the next 2 years.
Conference Coverage
AI tool reveals MS drug interactions, offers safer options
Deep learning–based methods are “useful” in screening for potential interactions both between drugs and with foods.
Conference Coverage
Ocrelizumab benefit confirmed in older patients with MS
Lower rates of relapse were seen in older patients taking ocrelizumab, but the risk for relapse in this age group is low.
Conference Coverage
Obesity linked to multiple ills in MS study
Subjects with excess weight progressed more rapidly and had more cognitive disability.
Conference Coverage
DMT discontinuation trial halted; MS returned in 17.8%
It’s still not clear when – or if – certain patients should take a break from MS therapy.
Conference Coverage
Even mild MS relapses may signal faster disability accumulation
Nondisabling relapses “should be considered in decisions to initiate or escalate treatment, including with high-efficacy therapies.”
Conference Coverage
Stem cell therapy strikes out in progressive MS
A retrospective study suggests no advantage of AHSCT over disease-modifying therapy in progressive MS.